Acorda Therapeutics Inc. (ACOR)
NASDAQ: ACOR
· Real-Time Price · USD
0.66
-0.21 (-24.14%)
At close: Apr 03, 2024, 3:59 PM
Acorda Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 20.29M | 37.98M | 27.71M | 29.68M | 22.26M | 31.47M | 33.51M | 31.05M | 22.53M | 36.97M | 31.46M | 31.79M | 28.86M |
Cost of Revenue | 3.71M | 13.29M | 3.39M | 3.06M | 3.23M | 4.56M | 11.01M | 8.8M | 5.97M | 4.2M | 13.3M | 11.32M | 11.96M |
Gross Profit | 16.58M | 24.7M | 24.33M | 26.61M | 19.02M | 26.91M | 22.51M | 22.25M | 16.57M | 32.77M | 18.15M | 20.46M | 16.9M |
Operating Income | -19.63M | 1.48M | -2.52M | -3.63M | -12.57M | 4.31M | -9.56M | -17.03M | -16.7M | -11.56M | -23.01M | -15.69M | -28.78M |
Interest Income | 207K | 222K | 157K | 58K | 93K | 1.87M | 17K | 20K | 1K | 1K | 1K | 1K | 3K |
Pretax Income | -27.28M | -255.87M | -9.94M | -11.35M | -18.86M | 21.58M | -12.44M | -20.12M | -24.26M | -18.9M | -30.18M | -23.39M | -36.6M |
Net Income | -27.39M | -217.76M | -8.89M | -9.38M | -16.82M | 19.14M | -13.85M | -46.68M | -24.52M | -20.57M | -27.07M | -22.86M | -33.45M |
Selling & General & Admin | 28.37M | 22.21M | 23.15M | 21.82M | 22.51M | 26.25M | 23M | 30.07M | 26.94M | 28.44M | 29.62M | 32.37M | 33.97M |
Research & Development | 954K | 1.01M | 1.21M | 1.55M | 1.39M | 1.2M | 1.38M | 1.52M | 1.69M | 1.37M | 1.93M | 2.37M | 4.75M |
Other Expenses | 11K | -158K | 403K | 1K | 7.69M | -4.86M | 7.69M | 7.69M | n/a | -7.34M | -7.17M | -7.71M | -7.82M |
Operating Expenses | 29.97M | 23.21M | 32.05M | 31.07M | 31.59M | 22.59M | 32.07M | 39.28M | 36.32M | 37.5M | 39.24M | 42.43M | 46.41M |
Interest Expense | 8.06M | 9.2M | 7.83M | 7.71M | 7.57M | 5.83M | 7.46M | 7.47M | 7.56M | 7.34M | 7.17M | 7.71M | 7.83M |
Selling & Marketing Expenses | n/a | 381K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 33.68M | 36.5M | 35.44M | 34.13M | 34.83M | 27.15M | 43.08M | 48.08M | 42.29M | 41.7M | 52.55M | 53.76M | 58.37M |
Income Tax Expense | 114K | -38.11M | -1.05M | -1.97M | -2.04M | 2.43M | 1.42M | 26.56M | 258K | 1.67M | -3.1M | -531K | -3.15M |
Shares Outstanding (Basic) | 1.24M | 964.38K | 1.24M | 1.24M | 1.22M | 1.22M | 1.21M | 839.15K | 662.55K | 591.63K | 556.55K | 499.21K | 473.5K |
Shares Outstanding (Diluted) | 1.24M | 964.38K | 1.24M | 1.24M | 1.22M | 1.1M | 1.21M | 864K | 662.55K | 592.95K | 556.55K | 499.6K | 473.5K |
EPS (Basic) | -22.06 | -225.81 | -7.16 | -7.55 | -13.83 | 15.73 | -11.41 | -55.63 | -37.01 | -34.69 | -48.64 | -45.76 | -70.65 |
EPS (Diluted) | -22.06 | -225.81 | -7.16 | -7.55 | -13.83 | 8.76 | -11.41 | -54.03 | -37.01 | -34.76 | -48.64 | -45.8 | -70.65 |
EBITDA | -12.67M | 9.4M | 372K | 3.24M | -4.47M | 12M | -6.45M | -12.46M | -11.22M | 9.79M | -11.48M | -20.56M | -22.54M |
EBIT | -19.64M | -238.69M | -6K | -6.52M | -11.29M | 27.4M | -4.97M | -12.64M | -17.61M | -5.56M | -23.01M | -15.69M | -28.78M |
Depreciation & Amortization | 882K | 7.92M | 7.69M | 7.69M | 8.1M | 7.69M | 3.12M | 4.57M | 8.53M | 7.69M | 7.69M | 7.69M | 7.69M |